Abstract

Acute bronchiolitis is the leading cause of lower respiratory tract infection and hospitalization in children less than 1 year of age worldwide. It is usually a mild disease, but some children may develop severe symptoms, requiring hospital admission and ventilatory support in the ICU. Infants with pre-existing risk factors (prematurity, bronchopulmonary dysplasia, congenital heart diseases and immunodeficiency) may be predisposed to a severe form of the disease.Clinical diagnosis of bronchiolitis is manly based on medical history and physical examination (rhinorrhea, cough, crackles, wheezing and signs of respiratory distress). Etiological diagnosis, with antigen or genome detection to identify viruses involved, may have a role in reducing hospital transmission of the infection.Criteria for hospitalization include low oxygen saturation (<90-92%), moderate-to-severe respiratory distress, dehydration and presence of apnea. Children with pre-existing risk factors should be carefully assessed.To date, there is no specific treatment for viral bronchiolitis, and the mainstay of therapy is supportive care. This consists of nasal suctioning and nebulized 3% hypertonic saline, assisted feeding and hydration, humidified O2 delivery. The possible role of any pharmacological approach is still debated, and till now there is no evidence to support the use of bronchodilators, corticosteroids, chest physiotherapy, antibiotics or antivirals. Nebulized adrenaline may be sometimes useful in the emergency room. Nebulized adrenaline can be useful in the hospital setting for treatment as needed. Lacking a specific etiological treatment, prophylaxis and prevention, especially in children at high risk of severe infection, have a fundamental role. Environmental preventive measures minimize viral transmission in hospital, in the outpatient setting and at home. Pharmacological prophylaxis with palivizumab for RSV bronchiolitis is indicated in specific categories of children at risk during the epidemic period.Viral bronchiolitis, especially in the case of severe form, may correlate with an increased incidence of recurrent wheezing in pre-schooled children and with asthma at school age.The aim of this document is to provide a multidisciplinary update on the current recommendations for the management and prevention of bronchiolitis, in order to share useful indications, identify gaps in knowledge and drive future research.

Highlights

  • Acute bronchiolitis is the leading cause of lower respiratory tract infection and hospitalization in children less than 1 year of age worldwide

  • Severe forms of the disease requiring hospitalization may be more frequent in children younger than 3 months of age or children with pre-existing risk factors such as prematurity, bronchopulmonary dysplasia, congenital heart diseases and immunodeficiency [2,7,8]

  • There is no evidence of efficacy for numerous therapies commonly used when treating bronchiolitis [11], and supportive treatment still remains the recommended approach, as confirmed by leading international guidelines, such as the guidelines issued by the American Academy of Pediatrics [2] (AAP)

Read more

Summary

Conclusion

Bronchiolitis is the leading cause of hospitalization in children younger than one year, and at times requires admission to the intensive care unit. Assistance provided to children with bronchiolitis is optimized by implementing shared strategies issued based on the most recent and robust scientific evidence concerning hospitalization criteria, diagnosis, monitoring, treatment. This will have a major favorable effect on these children, their families and on direct and indirect costs generated by the disease and by possible later outcomes. Author details 1SIMRI-Società Italiana per le Malattie Respiratorie Infantili, Italy. Author details 1SIMRI-Società Italiana per le Malattie Respiratorie Infantili, Italy. 2Women’s and Children’s Health Department, Unit of Pediatric Respiratory Medicine and Allergy, University of Padova, Via Giustiniani 3, 35128 Padova, Italy. 3SIN-Società Italiana di Neonatologia, Italy. 4SICP-Società Italiana di Cardiologia Pediatrica, Italy. 5AIEOP - Società Italiana di Ematologia e Oncologia Pediatrica, Italy. 6AMIETIP - Accademia Medica Infermieristica di Emergenza e Terapia Intensiva Pediatrica, Italy. 7FIMP - Federazione Italiana Medici Pediatri, Italy. 8SIAIP - Società Italiana di Allergologia e Immunologia Pediatrica, Italy. 9SICuPP Società Italiana delle Cure Primarie Pediatriche, Italy. 10SIEDP - Società Italiana di Endocrinologia e Diabetologia Pediatrica, Italy. 11SIFC - Società Italiana per lo studio della Fibrosi Cistica, Italy. 12SIGENP - Società Italiana Gastroenterologia Epatologia e Nutrizione Pediatrica, Italy. 13SIMEUP - Società Italiana di Medicina di Emergenza ed Urgenza Pediatrica, Italy. 14SIMGePeD - Società Italiana Malattie Genetiche Pediatriche e Disabilità Congenite, Italy. 15SIMP - Società Italiana di Medicina Perinatale, Italy. 16SINP - Società Italiana di Neurologia Pediatrica, Italy. 17SIPO - Società Italiana Pediatria Ospedaliera, Italy. 18SIPPS - Società Italiana di Pediatria Preventiva e Sociale, Italy. 19SISIP - Società Italiana di Scienze Infermieristiche Pediatriche, Italy. 20SITIP - Società Italiana di Infettivologia Pediatrica, Italy. 21SIP-Società Italiana di Pediatria, Italy

71. Robinson J
92. Thorburn K
Findings
98. Bollettino della Società Italiana di Cardiologia Pediatrica Anno 13
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call